Enlivex Therapeutics (NASDAQ:ENLV) Shares Up 16.5% – Time to Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) rose 16.5% on Friday . The stock traded as high as $1.24 and last traded at $1.20. Approximately 431,934 shares were traded during trading, an increase of 493% from the average daily volume of 72,780 shares. The stock had previously closed at $1.03.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a research report on Friday, February 7th.

Enlivex Therapeutics Trading Up 16.5 %

The stock has a fifty day simple moving average of $1.13 and a two-hundred day simple moving average of $1.26. The company has a market cap of $25.69 million, a PE ratio of -1.22 and a beta of 0.99.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.04. As a group, equities research analysts anticipate that Enlivex Therapeutics Ltd. will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in shares of Enlivex Therapeutics during the 4th quarter worth $26,000. Renaissance Technologies LLC boosted its holdings in Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after buying an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in Enlivex Therapeutics during the fourth quarter worth about $742,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.